Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis

M Roumiguié, X Paoletti, Y Neuzillet, R Mathieu… - Future …, 2021 - Future Medicine
Aim: Comparison of the efficacy/safety/health-related quality of life of apalutamide,
enzalutamide and darolutamide in Phase III clinical trials involving patients with …
被引用次数：14 相关文章

Apalutamide, Darolutamide and Enzalutamide in Nonmetastatic Castration-Resistant Prostate Cancer: A Meta-Analysis

M Roumiguié, X Paoletti, Y Neuzillet, R Mathieu… - Future …, 2021 - Taylor & Francis
Aim: Comparison of the efficacy/safety/health-related quality of life of apalutamide,
enzalutamide and darolutamide in Phase III clinical trials involving patients with …

Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis

M Roumiguié, X Paoletti, Y Neuzillet… - Future oncology …, 2021 - pubmed.ncbi.nlm.nih.gov
Aim: Comparison of the efficacy/safety/health-related quality of life of apalutamide,
enzalutamide and darolutamide in Phase III clinical trials involving patients with …

Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis.

M Roumiguié, X Paoletti, Y Neuzillet… - Future Oncology …, 2021 - europepmc.org
Aim: Comparison of the efficacy/safety/health-related quality of life of apalutamide,
enzalutamide and darolutamide in Phase III clinical trials involving patients with …

Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis

M Roumiguie, X Paoletti, Y Neuzillet, R Mathieu… - Future Oncology, 2021 - hal.science
Aim: Comparison of the efficacy/safety/health-related quality of life of apalutamide,
enzalutamide and darolutamide in Phase III clinical trials involving patients with …